Results 191 to 200 of about 46,577 (260)

Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis [PDF]

Anqi Zhang, Ting Sun, Dandan Yu, Rongfeng Fu, Xiao Fan Liu, Xue Feng, Wei Liu, Mankai Ju, Xinyue Dai, H. Dong, Wenjing Gu, Jia Chen, Ying Chi, Huiyuan Li, Wentian Wang, Renchi Yang, Yunfei Chen, Lei Zhang   +17 more
openalex   +1 more source

Successful Neutrophil Engraftment with Continued Ruxolitinib in Cord Blood Transplantation. [PDF]

Blood Cell Ther
Nagano T, Kondo T, Hiyama R, Ikeda D, Hayashino K, Inoue Y, Ueno M, Ueda Y, Kubota S, Kobayashi H, Seike K, Fujiwara H, Asada N, Ennishi D, Fujii K, Fujii N, Matsuoka KI, Maeda Y.   +17 more
europepmc   +1 more source

Ruxolitinib in the treatment of patients with myelofibrosis — questions and answers

, 2019
Krzysztof Warzocha, Wojciech Homenda, Andrzej Pluta, Tomasz Sacha, Maria Cioch, Marek Dudziński, Dorota Krochmalczyk, Joanna Góra‐Tybor, Ilona Seferyńska, Monika Joks, Marta Sobas   +10 more
openalex   +2 more sources

Gupta V, Tomuleasa C, Barranco Lampón GI, et al. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025;9(5):1105-1116. [PDF]

Blood Adv
europepmc   +1 more source

Sweet's syndrome with Koebner phenomenon triggered by G-CSF as a preleukemic manifestation in a patient with primary myelofibrosis: a case report. [PDF]

Front Med (Lausanne)
Zhang Z, Zhou D, Liu Y, Meng L, Ji B.
europepmc   +1 more source

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study [PDF]

Lindsay Rein, Firas El Chaer, Junichiro Yuda, Joseph M. Scandura, Shuichi Shirane, Kazuya Shimoda, Prithviraj Bose, Akiyoshi Takami, Alessandra Iurlo, Michiko Ichii, James McCloskey, Michael Keng, Samah Alimam, Noriko Fukuhara, Nikki Granacher, Giulia Benevolo, Alessandro Lucchesi, Tamanna Haque, Jean‐Jacques Kiladjian, Srinivas K. Tantravahi, Pankit Vachhani, Anand Patel, Stanley Cheung, Paul Yeh, Francesca Palandri, Ashwin Kishtagari, Ciro R. Rinaldi, Marcello Rotta, Vincent Ribrag, Michaël Loschi, Idoroenyi Amanam, Terrence Bradley, Karen Ansaldo, Masataka Seki, Guia Guffanti, Jinny Lee, Prasanthi Pellakuru, Zhonggai Li, Jason M. Foulks, Sujan Kabir, Jatin J. Shah, Raajit K. Rampal   +41 more
openalex   +1 more source

Correction to "Novel approaches in myelofibrosis". [PDF]

Hemasphere
europepmc   +1 more source

SF3B1 mutation as a predictive biomarker for luspatercept efficacy in myeloproliferative neoplasms and MDS/MPN: a clinical study. [PDF]

Ann Hematol
Cui T, Gong J, Zhang X, Zhang J, Wei N, Zheng W, Duan M.   +6 more
europepmc   +1 more source

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study [PDF]

Jan Philipp Bewersdorf, Andriy Derkach, Amer M. Zeidan, Emily Burton, K. Kan, M.E. Giuliani, Jeetayu Biswas, Michael J. Mauro, Brian Chernak, Tamanna Haque, Nikolai A. Podoltsev, Ross L. Levine, Prithviraj Bose, Raajit K. Rampal   +13 more
openalex   +1 more source